OBJECTIVES: Bipolar disorder (BD) is a mental illness of unknown neuropathology and has several genetic associations. Antipsychotics are effective for the treatment of acute mania, psychosis, or mixed states in individuals with BD. We aimed to identify gene transcripts differentially expressed in postmortem brains from antipsychotics-exposed individuals with BD (hereafter the 'exposed' group), non-exposed individuals with BD (hereafter the 'non-exposed' group), and controls. METHODS: We quantified the abundance of gene transcripts in postmortem brains from seven exposed individuals, seven non-exposed individuals, and 12 controls with the Affymetrix U133P2 GeneChip microarrays and technologies. We applied a q-value of ≤0.005 to identify statistically significant transcripts with mean abundance differences between the exposed, non-exposed and control groups. RESULTS: We identified 2191 unique genes with significantly altered expression levels in non-exposed brains compared to those in the control and exposed groups. The expression levels of these genes were not significantly different between exposed brains and controls, suggesting a normalization effect of antipsychotics on the expression of these genes. Gene ontology (GO) enrichment analysis showed significant (Bonferroni p ≤ 0.05) clustering of subgroups of the 2191 genes under many GO terms; notably, the protein products of genes enriched are critical to the function of synapses, affecting, for example, intracellular trafficking and synaptic vesicle biogenesis, transport, release and recycling, as well as organization and stabilization of the node of Ranvier. CONCLUSIONS: These results support a hypothesis of synaptic and intercellular communication impairment in BD. The apparent normalization of expression patterns with exposure to antipsychotic medication may represent a physiological process that relates both to etiology and improvement patterns of the disorder.
OBJECTIVES:Bipolar disorder (BD) is a mental illness of unknown neuropathology and has several genetic associations. Antipsychotics are effective for the treatment of acute mania, psychosis, or mixed states in individuals with BD. We aimed to identify gene transcripts differentially expressed in postmortem brains from antipsychotics-exposed individuals with BD (hereafter the 'exposed' group), non-exposed individuals with BD (hereafter the 'non-exposed' group), and controls. METHODS: We quantified the abundance of gene transcripts in postmortem brains from seven exposed individuals, seven non-exposed individuals, and 12 controls with the Affymetrix U133P2 GeneChip microarrays and technologies. We applied a q-value of ≤0.005 to identify statistically significant transcripts with mean abundance differences between the exposed, non-exposed and control groups. RESULTS: We identified 2191 unique genes with significantly altered expression levels in non-exposed brains compared to those in the control and exposed groups. The expression levels of these genes were not significantly different between exposed brains and controls, suggesting a normalization effect of antipsychotics on the expression of these genes. Gene ontology (GO) enrichment analysis showed significant (Bonferroni p ≤ 0.05) clustering of subgroups of the 2191 genes under many GO terms; notably, the protein products of genes enriched are critical to the function of synapses, affecting, for example, intracellular trafficking and synaptic vesicle biogenesis, transport, release and recycling, as well as organization and stabilization of the node of Ranvier. CONCLUSIONS: These results support a hypothesis of synaptic and intercellular communication impairment in BD. The apparent normalization of expression patterns with exposure to antipsychotic medication may represent a physiological process that relates both to etiology and improvement patterns of the disorder.
Authors: Jun Z Li; Marquis P Vawter; David M Walsh; Hiroaki Tomita; Simon J Evans; Prabhakara V Choudary; Juan F Lopez; Abigail Avelar; Vida Shokoohi; Tisha Chung; Omar Mesarwi; Edward G Jones; Stanley J Watson; Huda Akil; William E Bunney; Richard M Myers Journal: Hum Mol Genet Date: 2004-01-20 Impact factor: 6.150
Authors: Douglas A Hosack; Glynn Dennis; Brad T Sherman; H Clifford Lane; Richard A Lempicki Journal: Genome Biol Date: 2003-09-11 Impact factor: 13.583
Authors: Linda W Jurata; Yury V Bukhman; Vinod Charles; Frank Capriglione; Jeffrey Bullard; Andrew L Lemire; Ali Mohammed; Quyen Pham; Pascal Laeng; Jeffrey A Brockman; C Anthony Altar Journal: J Neurosci Methods Date: 2004-09-30 Impact factor: 2.390
Authors: Rui Chen; George I Mias; Jennifer Li-Pook-Than; Lihua Jiang; Hugo Y K Lam; Rong Chen; Elana Miriami; Konrad J Karczewski; Manoj Hariharan; Frederick E Dewey; Yong Cheng; Michael J Clark; Hogune Im; Lukas Habegger; Suganthi Balasubramanian; Maeve O'Huallachain; Joel T Dudley; Sara Hillenmeyer; Rajini Haraksingh; Donald Sharon; Ghia Euskirchen; Phil Lacroute; Keith Bettinger; Alan P Boyle; Maya Kasowski; Fabian Grubert; Scott Seki; Marco Garcia; Michelle Whirl-Carrillo; Mercedes Gallardo; Maria A Blasco; Peter L Greenberg; Phyllis Snyder; Teri E Klein; Russ B Altman; Atul J Butte; Euan A Ashley; Mark Gerstein; Kari C Nadeau; Hua Tang; Michael Snyder Journal: Cell Date: 2012-03-16 Impact factor: 41.582
Authors: D Lindberg; D Shan; J Ayers-Ringler; A Oliveros; J Benitez; M Prieto; R McCullumsmith; D-S Choi Journal: Curr Mol Med Date: 2015 Impact factor: 2.222
Authors: S Rangaraju; D F Levey; K Nho; N Jain; K D Andrews; H Le-Niculescu; D R Salomon; A J Saykin; M Petrascheck; A B Niculescu Journal: Mol Psychiatry Date: 2016-05-24 Impact factor: 15.992
Authors: H M Chen; C J DeLong; M Bame; I Rajapakse; T J Herron; M G McInnis; K S O'Shea Journal: Transl Psychiatry Date: 2014-03-25 Impact factor: 6.222
Authors: Kwi Hye Kim; Jiangang Liu; Rachelle J Sells Galvin; Jeffrey L Dage; Janice A Egeland; Rosamund C Smith; Kalpana M Merchant; Steven M Paul Journal: PLoS One Date: 2015-11-10 Impact factor: 3.240